Le Lézard
Classified in: Covid-19 virus
Subject: ATY

Gritstone bio, Inc. Class Action: The Gross Law Firm Reminds Gritstone Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 6, 2024 - GRTS


NEW YORK, July 3, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ: GRTS).

Shareholders who purchased shares of GRTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/gritstone-loss-submission-form/?id=88705&from=4

CLASS PERIOD: March 9, 2023 to February 29, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company would be unable to launch the Phase 2b CORAL Study, it's approved COVID-19 vaccine, in the timeframe it had represented to investors; (ii) the foregoing would impair Gritstone's ability to obtain external funding in connection with the Study, thereby negatively affecting Gritstone's ability to maintain its balance sheet and cash position; (iii) accordingly, Gritstone overstated its ability to successfully develop and commercialize its products; (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: August 6, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/gritstone-loss-submission-form/?id=88705&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of GRTS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 6, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm


These press releases may also interest you

at 08:20
The "Australia Gasoline Generator Market 2024-2030 Size, Trends, Segmentation, Revenue, Outlook, Companies, Share, Growth, Analysis, Value, Industry & Forecast: Market Forecast By Types, By Power Output, By End-Users, By Region and Competitive...

at 08:05
Wallbox Chargers, a global leader in electric vehicle charging and energy management solutions, announced the launch of the next generation of their Supernova DC fast charger, Supernova 220. The newest addition to the product family is designed to...

at 08:05
PennyMac Mortgage Investment Trust announced today the pricing of a private offering of secured term notes (the "Notes") in an aggregate principal amount of $355 million issued by the Company's indirect subsidiary, PMT ISSUER TRUST ? FMSR. The Notes...

at 08:00
Johnson & Johnson announced today that Health Canada, through a Priority Review, has issued a Notice of Compliance (NOC) for...

at 08:00
Gilsbar welcomes Diana Derbas as Project Management Director. In this role, she is responsible for developing and directing project management operations and strategic planning to meet key organizational goals. "This is a new role within...

at 07:40
"The Corporate Reputation of Pharma in 2023/2024: The Patient Perspective (Global Edition) - The Views of 2,500+ Patient Groups Worldwide" report has been added to ResearchAndMarkets.com's offering. Between November 2023 and late-February 2024, the...



News published on and distributed by: